Immunosuppression, myeloablation, and the use of immunologically immature tissue can overcome major histocompatibility complex barriers by inducing tolerance. With the goal of inducing tolerance to BALB/c-derived murine hybridoma cells producing the 4C6 monoclonal antibody (mAb), we transplanted BALB/c fetal tissue into neonatal pigs during a regimen of low-dose conditioning with busulfan and cyclophosphamide. After the tolerance induction phase, animals received intraperitoneal injections of 4C6 mAb hybridoma cells. Evidence of persistence of injected cells over time was sought by molecular analysis of peripheral blood for the presence of mouse genomic sequences and circulating 4C6 mAb. Persistence of donor polymerase chain reaction signal during the entire duration of the study, detectable mAb titer for 6 weeks, and a twofold increase of mAb concentration after a boost hybridoma infusion was observed in one animal receiving six consecutive administrations of the conditioning regimen. Our model has the distinctive advantage of allowing functional monitoring of engrafted cells for studying tolerance induction strategies. In addition, this model could be the basis for approaches aimed at producing mAbs in tolerized large animals.
O btaining stable chimerism through the induction of a state of immunologic tolerance is of major interest for the potential treatment of hematologic diseases (1) and organ transplantation (2) . In bone-marrow transplantation, myeloablative conditioning followed by hematopoietic stem-cell infusion results in engraftment of donor stem/progenitor cells followed by their differentiation into mature peripheral lineages (3) . Conditioning, however, is associated with severe side effects (3) . Recently, it was demonstrated that nonmyeloablative, fractioned total body irradiation (TBI), or lowdose chemotherapy combined with donor hematopoietic stem-cell infusion is sufficient to induce tolerance before consecutive allogeneic or xenogeneic organ transplantation (2, 4) . It was shown that as few as 1% hematopoietic donor cells are sufficient to induce a state of tolerance to donor-specific tissue (5, 6) .
The use of immunologically immature donor tissue (7) transplanted into an immunologically immature recipient is sufficient to induce long lasting microchimerism in animals and humans (8 -10) . In animal models of in utero transplantation, it has also been demonstrated that low-dose chemotherapy or TBI combined with peri-or postnatal reinfusion of donor hematopoietic cells can augment chimerism (11, 12) .
Here, we describe a xenogenic neonatal swine-mouse transplantation model aimed at tolerizing recipient animal to monoclonal antibody (mAb)-producing murine hybridoma cells. The traditional method, growing murine hybridoma cells as ascites tumor in pristane-treated syngenic mice, produces high yields of mAb. The extension of this approach to xenogeneic or allogeneic hybridoma usually results in rejection after intraperitoneal (IP) transplantation into murine recipients because of histocompatibility barriers. However, the engraftment of xenogenic hybridoma cells has been achieved in severe combined immunodeficiency mice with and without pretreatment (13) (14) (15) . Our transplantation procedure consisted of repetitions ("miniblocks") of low-dose chemotherapy conditioning followed by a tolerogenic ad-ministration of BALB/c fetal tissue that preceded the injection of BALB/c hybridoma cells.
Normal crossbred swine, Durok, Landrace, and Large White strains, were bred and maintained at the animal facility of the Institute Zooprofilattico Brescia, Italy according to the Italian veterinary regulations. The miniblock transplantation procedure started in neonatal pigs within 10 hours after birth and was repeated at 2-week intervals in one animal. Different concentrations of busulfan (0 -6 mg/kg body weight [BW]) combined with cyclophosphamide (0 -40 mg/kg BW) were tested in 10 neonatal pigs. Two animals receiving 6 mg/kg busulfan in a single administration died of infections (data not shown). All other animals survived without any symptoms of drug side effects and were fertile, delivering healthy offspring. Each miniblock consisted of a single, fixed dose of 2.4 mg busulfan (Busulfex Orphan Medical, Inc., Minnetonka, MN) administered on day 1. For dosage calculation (mg/kg BW), the weight of the animal was taken at the moment of injection. A single dose of 28 mg cyclophosphamide (Endoxan-Asta, Asta Medica AG, Frankfurt, Germany) was administered on day 2. Cell suspensions were prepared from seven murine fetuses surgically isolated from time mated BALB/c female mice killed at 14 days postcoitus and passed through a 120 m nylon mesh. On day 3, such cells were transplanted IP into recipient animals. Transplantation of fetal cells in conditioned animals (no. 401 and 402) was repeated six times at 2 weeks intervals. Control animal 760 did not receive conditioning and was subjected to three injections of fetal cells. Control DNA was extracted from peripheral blood cells and amplified by polymerase chain reaction (PCR) using murinespecific primers flanking an STR locus 1042, as previously reported (16) . To increase sensitivity, Southern blot analysis was performed as previously described (17) .
Furthermore, to demonstrate survival and activity of injected hybridoma cells, we titrated the presence of the mAb 4C6 in pig sera by an indirect enzyme-linked immunoadsorbent assay test using microplates coated with purified bovine IgG, sequentially incubated with pig sera, goat Igs, and antimouse Igs conjugated to peroxidase and substrate solution (18) .
Animal 401 received six miniblocks, and pig 402, a sibling of 401, received one conditioning miniblock followed by six administrations of murine fetal tissue ( Table 1) . The ani- The kinetics of the mAb titer in the serum of animals receiving transplant during the 90-day period after hybridoma injections are shown in Figure 1 . Minor fluctuations, just above the background level, were observed in animal 208, which was not treated with chemotherapy and fetal tissue but received hybridoma cell transplantation. Low and transient levels of mAb after both hybridoma injections were detectable in animal 402. Animal 401 showed mAb serum levels comparable with pig 402 after the first hybridoma injection; however, the mAb concentration in pig 401 was four times higher than in the other animals after the second hybridoma injection. The mAb titers decreased to background levels during the 6 weeks after injection. At different time points, the engraftment of BALB/c in neonatal pigs receiving transplants was detected by PCR amplification (Fig. 2A) In contrast, chimerism in animal 402 was only temporarily positive (lanes 4 and 6) and disappeared after the second hybridoma injection (lane 9). In animal 208, which did not undergo the transplantation procedure, chimerism was demonstrated at a low transient level (lane 7). The time correlation between chimerism analysis, transplantation protocol, and hybridoma infusion is summarized in Figure 2B .
To induce donor tolerance, we transplanted a cell suspension of entire donor fetuses, providing an intensive exposure to a wide range of xenogenic fetal antigens into immature and immunosuppressed recipients. In our miniblock transplantation protocol, single, low-dose cyclophosphamide combined with busulfan in liquid form to avoid highly variable serum busulfan concentrations after oral administration were infused IP (19, 20) . Repeated, single, low-dose administrations allowed the increase of total dosage per kilogram of BW while still avoiding severe side effects.
Animals received transplants with hybridoma cells of BALB/c origin and thus major histocompatibility complex identical with the fetal tissue. Consecutive transplantation of fetal BALB/c donor tissue lead to hematopoietic chimerism detected in the peripheral blood, indicating that donor cells actively migrated into the peripheral blood system. The signal of chimerism and the concentration of mAb after both hybridoma injections followed a similar pattern. Only chimeric animals showed mAb titers in their serum. Interestingly, higher total dosage per kilogram of BW of chemotherapy was observed to raise mAb titers. The disappearance of the mAb titers in the serum in both animals could be explained by immunologic donor rejection. However, the increase of the mAb titer after the second injection and the coexisting presence of chimerism in the animal receiving six miniblock transplants suggest the induction of tolerance. The disappearance of the mAb titer thus might be a consequence of a lack of physiologic growth support by the host. Our data indicate that temporary production of murine mAb in xenogenic pigs can be achieved by low-dose chemotherapy combined with syngeneic murine fetal tissue transplantation before the infusion of murine hybridoma cells.
Finally, our animal transplantation model will allow further investigation of the effect of concentration of chemotherapeutic drugs, the optimal number of miniblocks, and the choice of donor tissue on tolerance induction strategies. The kinetic effect of mAb titer in the serum in combination with PCR chimerism analysis constitute a read-out system for hybridoma-cell transplantation, giving information on the state of tolerance, engraftment, and functionality. In addition, maintaining continuously high levels of mAb in the serum of a large animal may allow the isolation of a high quantity of mAbs.
